title: Experts point to lessons learned from controversy over rofecoxib safety.
authors.forename: Tracy
authors.initials: T
authors.lastname: Hampton
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000191:economics; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000191:economics; D013450:Sulfones / Q000009:adverse effects* / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib